WCLC 2025 - Posters & ePosters-P2.06.14 Adoption of a 50-Gene Targeted Next Generation Sequencing Hotspot Panel in Non-Small Cell Lung Cancer in a Tertiary Institution in Singapore

P2.06.14 Adoption of a 50-Gene Targeted Next Generation Sequencing Hotspot Panel in Non-Small Cell Lung Cancer in a Tertiary Institution in Singapore

Back to course

Pdf Summary

This study from the National University Cancer Institute Singapore reports on adopting a laboratory-developed 50-gene targeted next-generation sequencing (NGS) hotspot panel (APEX Tissue, MiRXES) for molecular profiling in non-small cell lung cancer (NSCLC) patients. Between June 2023 and March 2025, patients with newly diagnosed NSCLC underwent NGS testing, and their clinicopathological and molecular data were prospectively collected. Outcomes were compared to a historic cohort of advanced NSCLC patients tested by single-gene testing (SGT) from January 2020 to May 2023.<br /><br />Key findings include a significantly higher detection of actionable genomic alterations (AGAs) using the 50-gene NGS panel compared to SGT (62.7% vs. 23%, p=0.01). Consequently, more patients in the NGS group received targeted therapies (56.7% vs. 23%, p=0.01). The median turnaround times were comparable between NGS (9.01 days) and SGT (7.89 days). Importantly, clinical outcomes were better in the NGS group: the objective response rate (ORR) was 53.2% versus 34.2% with SGT (p=0.01).<br /><br />Survival analysis revealed that patients tested by NGS had significantly longer progression-free survival (PFS) — median 14.8 months versus 8.8 months (adjusted hazard ratio [HR] 0.57; p=0.01) — and overall survival (OS) — median 19.8 months versus 14.0 months (adjusted HR 0.55; p=0.01). Adjustments accounted for age, gender, ethnicity, smoking status, ECOG performance status, and PD-L1 expression.<br /><br />The study concludes that adoption of targeted NGS testing improves the identification of actionable mutations and is associated with better treatment responses and survival in advanced NSCLC patients compared to single-gene testing. This supports the use of multi-gene NGS panels as the standard molecular diagnostic approach in this setting.

Asset Subtitle

Kenneth Sooi

Meta Tag

Speaker Kenneth Sooi

Topic Pathology and Biomarkers

Keywords

non-small cell lung cancer

NSCLC

next-generation sequencing

NGS

single-gene testing

SGT

actionable genomic alterations

targeted therapy

progression-free survival

overall survival